Riskpilot← Back to searchSign inGet full accessGENINOVA AS
ASActiveOrg 983568823Storhamargata 44, 2317 HamarResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20010 employeeswww.norsvin.no
Revenue 2024
NOK 0
EBITDA margin
—
-34% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
NOK -7K
-147% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -40K | -34% |
| Net profit | NOK -7K | -147% |
| Total assets | NOK 766K | -1% |
| Equity | NOK 766K | -1% |
| Employees | 0 | — |
Legal name
GENINOVA AS
Org number
983568823
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4. august 2001
Share capital
NOK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene eller daglig leder alene.
Company purpose
Drive prosjekt basert forskning- og utviklingsarbeid innenfor avlsforskning med henblikk på å utnytte eierselskapenes kompetanse og erfaringer innen ulike grener innen genetikk, statistikk og avlsteknologi.
Address
Storhamargata 44, 2317 Hamar
Website
www.norsvin.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −14 | −25 | −20 | −30 | −40 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −14 | −25 | −20 | −30 | −40 |
| Net financials | 3 | 1 | 10 | 27 | 32 |
| Profit before tax | −11 | −24 | −9 | −3 | −7 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −11 | −24 | −9 | −3 | −7 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 810 | 786 | 777 | 774 | 766 |
| Equity | 810 | 786 | 777 | 774 | 766 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 0 | 0 | 0 | 0 |
| Total debt | 0 | 0 | 0 | 0 | 0 |
EBITDA margin
-3978200.0%
This company
15.8%
Market median
-25178581% vs market
20202024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20202024
Return on equity
-1.0%
This company
18.4%
Market median
-105% vs market
20202024
Net profit margin
-744900.0%
This company
8.1%
Market median
-9196396% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ES Chief Executive Officer | Chief Executive Officer | 2015 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2016 | |
| Board of Directors | 2024 | |
| Chairman | 2016 | |
| Former (1) | ||
| Board of Directors | 2016 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2024 | |
| Company | 50% | 50% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Norsvin Sa
GENINOVA AS Board members of GENINOVA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erling Sehested | Chief Executive Officer | 0 companies |
| Odd Magne Rødseth | Board of Directors | 0 companies |
| Knut Kvitvang Røflo | Board of Directors | 0 companies |
| Nina Santi | Board of Directors | 0 companies |
| Olav Eik-Nes | Chairman | 0 companies |